Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) was featured in a recent H.C. Wainwright Key Opinion Leader event focused on oncolytic immunotherapies in breast and pancreatic cancers. The event highlighted discussions from two prominent experts:
Dr. Martine Piccart, Honorary Professor at Université Libre de Bruxelles and Scientific Director at Institut Jules Bordet, provided insights on HR+/HER2- metastatic breast cancer and emphasized the potential of pelareorep in activating immune responses against cancer.
Dr. Alexander Eggermont, Professor at University Medical Center Utrecht, discussed current treatment standards for pancreatic ductal adenocarcinoma (PDAC) and explored pelareorep's potential impact in treating this resistant form of cancer.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) è stata protagonista di un recente evento H.C. Wainwright Key Opinion Leader incentrato sulle immunoterapie oncolitiche nei tumori al seno e al pancreas. L'evento ha messo in evidenza le discussioni di due esperti di spicco:
La Dott.ssa Martine Piccart, Professoressa Onoraria presso l'Université Libre de Bruxelles e Direttrice Scientifica dell'Institut Jules Bordet, ha fornito approfondimenti sul cancro al seno metastatico HR+/HER2- e ha sottolineato il potenziale di pelareorep nell'attivare le risposte immunitarie contro il cancro.
Il Dott. Alexander Eggermont, Professore presso il University Medical Center Utrecht, ha discusso gli attuali standard di trattamento per l'adenocarcinoma duttale pancreatico (PDAC) ed esplorato il potenziale impatto di pelareorep nel trattamento di questa forma resistente di cancro.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) fue presentada en un reciente evento H.C. Wainwright Key Opinion Leader centrado en las inmunoterapias oncolíticas para el cáncer de mama y páncreas. El evento destacó las discusiones de dos expertos destacados:
La Dra. Martine Piccart, Profesora Honoraria en la Université Libre de Bruxelles y Directora Científica en el Institut Jules Bordet, proporcionó información sobre el cáncer de mama metastásico HR+/HER2- y enfatizó el potencial de pelareorep para activar respuestas inmunitarias contra el cáncer.
El Dr. Alexander Eggermont, Profesor en el University Medical Center Utrecht, discutió los estándares actuales de tratamiento para el adenocarcinoma ductal pancreático (PDAC) y exploró el impacto potencial de pelareorep en el tratamiento de esta forma resistente de cáncer.
온콜리틱스 바이오텍® 주식회사 (NASDAQ: ONCY) (TSX: ONC)는 유방암 및 췌장암에 대한 온콜리틱 면역 요법에 중점을 둔 최근의 H.C. 웨인라이트 키 오피니언 리더 이벤트에 소개되었습니다. 이 이벤트에서는 두 명의 저명한 전문가가 논의한 내용이 강조되었습니다:
마르틴 피카르 박사, 브뤼셀 자유 대학교의 명예 교수이자 쥴 보르데 연구소의 과학 이사, HR+/HER2- 전이성 유방암에 대한 통찰력을 제공하고 펠라레오렙이 암에 대한 면역 반응을 활성화하는 잠재력을 강조했습니다.
알렉산더 에거몬트 박사, 유트레히트 대학 의료 센터의 교수는 췌관 선암(PDAC)에 대한 현재 치료 기준을 논의하고 이 저항성 암 치료에서의 펠라레오렙의 잠재적 영향을 탐구했습니다.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) a été présenté lors d'un récent événement H.C. Wainwright Key Opinion Leader axé sur les immunothérapies oncolytiques dans les cancers du sein et du pancréas. L'événement a mis en avant les discussions de deux experts de renom :
Dr. Martine Piccart, Professeur Honoraire à l'Université Libre de Bruxelles et Directrice Scientifique à l'Institut Jules Bordet, a fourni des informations sur le cancer du sein métastatique HR+/HER2- et a souligné le potentiel de pelareorep pour activer les réponses immunitaires contre le cancer.
Dr. Alexander Eggermont, Professeur au Centre Médical Universitaire d'Utrecht, a discuté des normes de traitement actuelles pour l'adénocarcinome canalaire pancréatique (PDAC) et a exploré l'impact potentiel de pelareorep dans le traitement de cette forme résistante de cancer.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) wurde kürzlich in einem H.C. Wainwright Key Opinion Leader Event vorgestellt, das sich auf onkolytische Immuntherapien bei Brust- und Bauchspeicheldrüsenkrebs konzentrierte. Die Veranstaltung hob die Diskussionen von zwei prominenten Experten hervor:
Dr. Martine Piccart, Ehrenprofessorin an der Université Libre de Bruxelles und wissenschaftliche Direktorin am Institut Jules Bordet, gab Einblicke in HR+/HER2- metastasierenden Brustkrebs und betonte das Potenzial von pelareorep zur Aktivierung immunologischer Reaktionen gegen Krebs.
Dr. Alexander Eggermont, Professor am Universitätsklinikum Utrecht, erörterte die aktuellen Behandlungsstandards für das duktale Adenokarzinom der Bauchspeicheldrüse (PDAC) und untersuchte das potenzielle Einfluss von pelareorep auf die Behandlung dieser resistenten Krebsform.
- None.
- None.
Martine Piccart, M.D., Ph.D., an Honorary Professor of Oncology at the Université Libre de
Alexander Eggermont, M.D., Ph.D., Professor of Clinical & Translational Immunotherapy at the University Medical Center Utrecht in
A replay of the full conversation can be found by clicking here.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track Designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Logo: https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-and-pelareorep-discussed-during-recent-hc-wainwright-key-opinion-leader-event-on-oncolytic-immunotherapies-in-breast-and-pancreatic-cancers-302425541.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What was discussed about ONCY's pelareorep at the H.C. Wainwright KOL event?
Which key opinion leaders presented at the ONCY H.C. Wainwright event in April 2025?
What types of cancer is ONCY's pelareorep being evaluated for?
How does ONCY's pelareorep work in cancer treatment?
